Skip to main content

Horizons Marijuana Life Sciences ETF(HMMJ-T)
TSX

Today's Change
Real-Time Last Update

Closing Bell: Horizons Marijuana Life Sciences ETF down on Wednesday (HMMJ)

Automated Summaries - The Globe and Mail - Wed Apr 10, 4:02PM CDT

Horizons Marijuana Life Sciences ETF opened trading today at $10.61 and closed at $10.71. Intraday prices ranged from a low of $10.60 to a high of $10.94.

Share prices decreased -1.20 percent from the previous day's close of $10.84.

During the day across North America, the TSX Composite closed 0.46% at 22361.78, the S&P 500 closed 0.14% at 5209.91, the Dow Jones Industrial Average closed -0.02% at 38883.67 and the Nasdaq Composite closed 0.32% at 16306.64.

Horizons Marijuana Life Sciences ETF traded under HMMJ on the Toronto Stock Exchange (TSX).

A total of 7,940 shares was traded during the session, with total trades of 57. On average, Horizons Marijuana Life Sciences ETF has traded 15,742 shares in the last five days and 13,402 year-to-date.

The TSX overall saw 976 price advancers against 4,291 declines and 93 unchanged.

During the prior 52 weeks, HMMJ.TO has traded as high as $11.91 (April 04,2024) and low as $8.07 (October 27,2023). Moreover, in the last 12 months, Horizons Marijuana Life Sciences ETF's shares have advanced 1.61 percent, while this year, they have boosted 15.29%.

Following today's trading, Horizons Marijuana Life Sciences ETF has a market capitalization of $89.33 million on a float of 8,241 shares outstanding. Its annual EPS is $None.

Horizons Marijuana Life Sciences ETF is a None company headquartered in, None.

The Horizons Marijuana Life Sciences Index ETF seeks to replicate, to the extent possible, the performance of the North American Marijuana Index, net of expenses. The Index is designed to provide exposure to the performance of a basket of North American publicly listed life sciences companies with significant business activities in the marijuana industry..

Horizons Marijuana Life Sciences ETF is holding an average recommendation of "Strong Sell" from 0.00 analysts according to Zacks. Currently, there are for the stock.

AI at The Globe and Mail
This report is produced using automated technology that summarizes market data into articles for our readers. Ongoing project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities..

More from The Globe